ARID4B

Across TCGA pan-cancer cohorts, ARID4B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARID4B data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ARID4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARID4B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

BRCA, OV, and SCLC are the cancer types where ARID4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.103	0.579	.001	36	view →
OV	OS	Median	II,III,IV	0.346	0.843	.003	18	view →
SCLC	OS	Median	All	0.082	0.822	<.001	18	view →
CHOL	OS	Median	All	0.154	0.793	.004	9	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
SKCM	OS	Median	III,IV	0.232	0.697	.046	5	view →
COAD	OS	Median	II,III,IV	0.649	0.853	.039	2	view →
GBM	DFS	Median	All	1.000	0.248	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARID4B–BRCA (OS)

Open the BRCA breakdown →